

THE MTA STAR LISTING PROCESS: BOARD OF DIRECTORS OF PHARMANUTRA S.P.A.

Pisa, 23rd October 2020 - [PharmaNutra S.p.A.](#) (the "Company"), nutraceutical company, leader in the iron nutritional supplements sector, listed on the AIM Italia Market (Ticker: PHN), further to the press release circulated on 13rd October last, communicates that its Board of Directors meeting today made, as part of the listing process on the Mercato Telematico Azionario organised and managed by Borsa Italiana S.p.A., STAR Segment ("MTA"), the following **decisions on governance**:

- (i) establishment of a Remunerations and Appointments Committee made up of the independent Directors Alessandro Calzolari, Marida Zaffaroni and Giovanna Zanotti, appointing Ms Zanotti as President;
- (ii) establishment of a Control and Risks Committee made up of the independent Directors Alessandro Calzolari, Marida Zaffaroni and Giovanna Zanotti, appointing Ms Zaffaroni as President;
- (iii) establishment of a Related Parties Committee made up of the independent Directors Alessandro Calzolari, Marida Zaffaroni and Giovanna Zanotti, appointing Mr Calzolari as President;
- (iv) approval of the new texts of the following internal procedures: (a) "Procedure for the management and communication of privileged information"; (b) "Procedure related to holding the register of those with access to privileged information"; (c) "Procedure related to internal dealing obligations"; and (d) "Procedure for transactions with related parties";
- (v) appointment of the Vice President and Executive Director, Roberto Lacorte, as Director In charge of the internal control and risks management system;
- (vi) appointment of Pasquale Giovinazzo, from outside the Company, as Head of Internal Audit;
- (vii) appointment of the Independent Director, Alessandro Calzolari, as lead independent director.

The above resolutions becoming effective is subordinate to the date Company shares begin trading on the MTA.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
investorrelation@pharmanutra.it
Internal Press Office
press@calabughi.com

**Nomad
CFO SIM S.p.A.**

Via dell'Annunciata, 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfsim.com

**Press Office
Spriano Communication & Partners**

Via Santa Radegonda, 16
20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com